AstraZeneca
A research-based global biopharmaceutical company.
AstraZeneca Annual Report 2024AstraZeneca is a research-based biopharmaceutical company formed in 1999 through the merger of Astra AB and Zeneca Group. Headquartered in Cambridge, England, the company operates globally and is publicly listed on exchanges including the Nasdaq.
The company focuses on five primary therapy areas: Oncology, Cardiovascular, Renal and Metabolism, Respiratory & Immunology, Infectious Disease, and Rare Disease via its Alexion subsidiary. Its portfolio includes notable medicines such as Tagrisso for non-small cell lung cancer and Farxiga for cardiometabolic treatment.
With 2024 total revenue of $54.07 billion, AstraZeneca is positioned among the top tier of global pharmaceutical firms. The company employs a science-led strategy with an extensive clinical pipeline and has been recognized for its efforts in expanding access to key medicines through voluntary licensing.